ByTrending Posts
Merck’s Bold Pivot: Can Dividing Oncology from the…
Merck’s audacious restructuring of its pharmaceutical operations into standalone oncology and non-oncology divisions isn’t mere corporate tinkering—it’s a…
Lilly’s $2.4B Bet on In Vivo CAR-T: Acquiring…
Eli Lilly and Company revealed plans in early February 2026 to acquire Orna Therapeutics, a cutting-edge biotech company…
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus…
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its…
Is Bayer’s Lawsuit Against Johnson & Johnson Escalating…
Leverkusen, Germany — Bayer AG has filed a lawsuit in U.S. federal court against Johnson & Johnson, alleging…
Is Johnson & Johnson’s $1 Billion Pennsylvania Investment…
New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1 billion to construct…
Is Johnson & Johnson Preparing to Divest DePuy…
Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is reportedly exploring a…
Can Unnatural Products and Novartis Unlock “Undruggable” Cardiovascular…
Santa Cruz, Calif., February, 2026 — Unnatural Products, Inc. (UNP) today announced a research collaboration and licensing agreement…
Can Foundation Medicine and Manifold Redefine Precision Oncology…
Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics…
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…
Trending Posts
Latest Stories
Indian Biopharma Faces Freight Surge Amid US-Iran Escalation
India’s biopharma sector confronts $300-500M export losses as US-Iran war disrupts Gulf shipping, spiking container…
What broader implications does Zealand Pharma’s petrelintide trial setback raise for the GLP-1 obesity market?
Trial Context Recap ZUPREME-1 delivered 10.7% peak weight loss over 42 weeks across 493 patients,…
The $10B+ Pharma Titans of 2025: Fortress Builders or House of Cards?
In 2025, only nine pharmaceutical brands crossed the $10 billion revenue threshold, collectively generating $125B+ while representing 25% of global…
How Does Eli Lilly Secure $100B+ Obesity Dominance Through 8 Triple/Triple+ Agonist Launches by 2030?
Eli Lilly establishes unrivaled obesity leadership through its 40 Phase 2/3 programs and 34 discovery-stage assets, commanding 60% US GLP-1 market…
Gallery
